NEW YORK (GenomeWeb news) – ARUP Laboratories, a diagnostic testing services provider in Salt Lake City, has licensed a biomarker from Epigenomics for use in developing an early detection test for colorectal cancer.

Berlin, Germany-based Epigenomics said today that ARUP has signed a non-exclusive license to use the DNA methylated Septin 9 gene to develop a test for colorectal cancer from a patient's blood sample.

The company said that it has demonstrated that methylated DNA of the Septin 9 gene indicates colorectal cancer in the early stages.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.